GlassScriptPhysician profile
Lawrence J Parsons
NPI 1972021244
$8,410.07
in general payments reported to CMS, 2019-2025
32 companies · $3,279 in 2025
The $3,279 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $250 · 2022: $227 · 2023: $2,255 · 2024: $2,399 · 2025: $3,279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,933.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,933.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,586.26 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,441.85 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $752.73 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Phathom Pharmaceuticals, INC. | $666.84 | 2023-2025 | Voquezna |
| Ardelyx, INC. | $599.12 | 2022-2025 | Ibsrela |
| Janssen Biotech, INC. | $520.90 | 2022-2025 | Tremfya, Stelara, Simponi |
| Gilead Sciences, INC. | $435.09 | 2023-2025 | |
| Madrigal Pharmaceuticals | $326.64 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $241.91 | 2022-2024 | Linzess |
| Pfizer INC. | $221.44 | 2023-2025 | |
| Celgene Corporation | $210.09 | 2023-2024 | Zeposia |
| Lilly USA, LLC | $173.56 | 2024-2025 | Omvoh |
| Fresenius Kabi USA, LLC | $153.45 | 2023-2024 | Idacio |
| Exact Sciences Corporation | $144.82 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Intercept Pharmaceuticals, INC. | $123.29 | 2022-2025 | Ocaliva |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $113.90 | 2023-2025 | Sutab, Suflave |
| Qol Medical, LLC | $90.49 | 2025 | Sucraid |
| Ferring Pharmaceuticals INC. | $87.28 | 2023-2025 | Rebyota |
| Alnylam Pharmaceuticals INC. | $73.76 | 2023-2025 | Givlaari |
| Celltrion USA INC. | $67.47 | 2025 | Vegzelma |
| Mallinckrodt Hospital Products INC. | $48.54 | 2024 | Terlivaz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.48 | 2024 | Cyltezo |
| Aimmune Therapeutics, INC. | $41.41 | 2025 | Zenpep |
| Regeneron Healthcare Solutions, INC. | $39.35 | 2023-2024 | Dupixent |
| Cumberland Pharmaceuticals, INC. | $36.99 | 2023 | Kristalose |
| Novo Nordisk INC | $32.83 | 2025 | Wegovy |
| Biocon Biologics INC | $29.97 | 2025 | Yesintek |
| Redhill Biopharma INC. | $29.04 | 2021-2023 | Talicia |
| Genzyme Corporation | $25.26 | 2025 | |
| Nestle Healthcare Nutrition INC. | $20.79 | 2023 | |
| Evoke Pharma, INC. | $17.03 | 2025 | |
| Amgen INC. | $16.49 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Parsons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.